華納藥(yao)(yao)(yao)廠近(jin)期接受(shou)投資者(zhe)調研(yan)(yan)時表示，目前，在創(chuang)(chuang)新藥(yao)(yao)(yao)研(yan)(yan)發(fa)方面，公(gong)司在研(yan)(yan)的(de)中藥(yao)(yao)(yao)1類(lei)創(chuang)(chuang)新藥(yao)(yao)(yao)乾清顆(ke)粒(li)已(yi)完成I期臨(lin)床試(shi)驗，已(yi)進入II期臨(lin)床試(shi)驗；公(gong)司控股子公(gong)司致(zhi)根醫藥(yao)(yao)(yao)承擔的(de)ZG-001研(yan)(yan)發(fa)項目，已(yi)完成臨(lin)床前研(yan)(yan)究，并按計(ji)劃(hua)推進下一步研(yan)(yan)發(fa)工作(zuo)；公(gong)司參股公(gong)司天璣(ji)珍稀承擔的(de)ZY-022項目已(yi)經完成臨(lin)床前研(yan)(yan)究，并按計(ji)劃(hua)推進下一步研(yan)(yan)發(fa)工作(zuo)。（界面）